Virpax Pharmaceuticals (VRPX) AI Stock Analysis

• Market Cap: $372.25K
• Dividend Yield: N/A
• Average Volume (3M): 213.63K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.60
• Revenue Growth: N/A
• EPS Growth: 60.26%
• Country: US
• Employees: 2
• Sector: Healthcare
• Sector Strength: 53
• Industry: Biotechnology
• EPS (TTM): -128.83
• Shares Outstanding: 1,242,504
• 10 Day Avg. Volume: 11,176
• 30 Day Avg. Volume: 213,631
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 11.13
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 1

Virpax Pharmaceuticals is facing significant financial challenges with zero revenue and high cash burn, making its financial performance the most critical factor. Technical indicators show a strong bearish trend, compounded by a delisting notice and leadership changes. The recent capital raise offers some hope, but overall, the outlook remains risky and uncertain.

Positive Factors

Safety Profile

The Molecular Envelope Technology (MET) study found no moderate-to-severe adverse events, indicating safety.

Study Results

Probudur found to successfully reduce pain in rat model, with positive study results consistent with prior studies.

Negative Factors

Financial Constraints

Insufficient capital to materially advance into Phase 2 studies for both Probudur and Envelta.

Leadership Instability

Virpax's CEO and CFO both resigned, along with multiple board members, due to disagreements with execution of policies, practices, and procedures.

Regulatory Compliance

Virpax received a deficiency letter from Nasdaq since the stock was trading below <$1 for 30 consecutive business days and has until a specific date to regain compliance.

Virpax Pharmaceuticals Business Overview & Revenue Model

Company Description

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical nonsteroidal anti-inflammatory drug treatment for chronic osteoarthritis of the knee; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise PES200, which enables the delivery of a metabolically labile peptide drug into the brain; AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and VRP324, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.

How the Company Makes Money

Virpax Pharmaceuticals makes money through the development and commercialization of its proprietary drug delivery systems and pharmaceutical products. The company's revenue model includes licensing agreements with other pharmaceutical companies and partnerships to co-develop and market their drug candidates. Additionally, Virpax seeks to generate income from milestone payments and royalties derived from successful commercialization of their therapies. Key revenue streams include developmental collaborations and strategic alliances with industry partners that enable the advancement of their product pipeline.

Virpax Pharmaceuticals Financial Statement Overview

Summary

Virpax Pharmaceuticals shows significant financial instability with zero revenue and increasing net losses. The negative stockholders' equity and persistently negative operating cash flow highlight the company's reliance on external financing, posing substantial long-term sustainability risks.

Income Statement

Virpax Pharmaceuticals has consistently reported zero revenue, indicating the company is pre-revenue or has not yet commercialized its products. The net losses over the years have widened significantly, with a substantial increase in operating expenses reflected in the negative EBIT and EBITDA. This trend suggests ongoing R&D investment or operational challenges without corresponding revenue generation.

Balance Sheet

The company's financial structure is concerning, with negative stockholders' equity indicating insolvency issues, exacerbated by increasing liabilities and a decreasing asset base. The debt-to-equity ratio is not applicable due to zero debt, but the negative equity highlights a risky financial position needing immediate address to ensure operational continuity.

Cash Flow

Operating cash flow is persistently negative, showcasing cash burn typical of a biotech firm in developmental stages. No free cash flow growth and reliance on financing activities for cash inflow highlight sustainability risks. The absence of revenue and high cash outflows foreshadow long-term liquidity challenges if financing cannot be secured.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00
	Gross Profit
0.00	0.00	0.00	0.00	0.00
	EBIT
-12.08B	-15.69M	-21.85M	-12.03M	-4.20M
	EBITDA
-12.08B	-15.19M	0.00	0.00	-4.19M
	Net Income Common Stockholders
-12.07B	-15.19M	-21.46M	-12.15M	-4.49M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
1.51B	9.14M	19.00M	36.84M	54.80K
	Total Assets
1.56B	9.63M	19.67M	39.57M	465.41K
	Total Debt
0.00	0.00	0.00	0.00	1.57M
	Net Debt
-1.51M	-9.14M	-19.00M	-36.84M	1.51M
	Total Liabilities
2.47B	7.69M	3.09M	2.09M	4.68M
	Stockholders Equity
-913.76M	1.93M	16.58M	37.48M	-4.22M
Cash Flow		Free Cash Flow
-16.71B	-9.85M	-17.85M	-14.54M	-1.38M
	Operating Cash Flow
-16.71B	-9.85M	-17.85M	-14.54M	-1.38M
	Investing Cash Flow
0.00	0.00	0.00	0.00	0.00
	Financing Cash Flow
9.08B	0.00	0.00	51.33M	1.40M

Virpax Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.30
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VRPX, the sentiment is Negative. The current price of 0.3 is above the 20-day moving average (MA) of 0.26, below the 50-day MA of 1.94, and below the 200-day MA of 12.06, indicating a bearish trend. The MACD of -0.44 indicates Negative momentum. The RSI at 19.27 is Positive, neither overbought nor oversold. The STOCH value of 45.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VRPX.

Virpax Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$5.23B	3.70	-41.86%	2.84%	16.58%	-0.16%
GRI	45 Neutral	$1.39M	―	-382.57%	―	―	98.55%
VRPX	31 Underperform	$372.25K	―	-2364.82%	―	―	60.26%
SLRX	30 Underperform	$1.56M	―	-164.02%	―	―	79.57%
PCSA	29 Underperform	$3.10M	―	-354.51%	―	―	56.26%
SCPX	23 Underperform	$557.45K	―	-174.06%	―	-10.75%	82.25%
VINC	15 Underperform	$1.44M	―	-431.29%	―	―	48.17%

Virpax Pharmaceuticals Corporate Events

Virpax Pharmaceuticals Faces Nasdaq Delisting Notice and Leadership Changes

On April 2, 2025, Virpax Pharmaceuticals received a delisting notice from the Nasdaq Hearings Panel due to non-compliance with the minimum stockholders’ equity requirement. The company’s stock trading will be suspended on April 4, 2025, with delisting finalized after the appeal period. Additionally, on the same day, several board members and the CFO resigned, with no disagreements cited as the cause.

Virpax Pharmaceuticals Appoints Charn Deol as Independent Director

On February 5, 2025, Virpax Pharmaceuticals appointed Charn Deol as an independent director following the resignation of Jaydriane Panis. Mr. Deol, with over 35 years of public company management experience, will also serve as Chair of the Audit Committee and join the Compensation and Nominating and Corporate Governance Committees. His appointment is expected to enhance Virpax’s strategic oversight, leveraging his extensive experience in guiding Canadian companies through public market regulatory processes.